From the Professor..., page-48

First 48 Last

Share
Profile

Follow
GinoE

771 Posts.

297

14/05/24

06:59

Post #: 73807295
Share

Originally posted by Taureanbull: ↑

“disease control rate of 50% across a broad spectrum of solid tumor types in a phase 1 dose escalation trial is an amazing result and validation of the groundbreaking science being developed by Imugene.”

HArry, As you said “amazing result”. There are two factors to consider here. Firstly this is a Ph1 trial. And it is showing that patients need healthy stem cell diversity. That’s the reason we are doing a ph1 trial. To collect this important data.

Yuman FONG said “CF33 works in all cancers!” He did not say “ it works in all patients “. So we now know that CF33 works best as a first line of therapy. Whilst the current patients have failed on 2,3 or even 4 lines of therapy, their immune system has been severely suppressed by these previous highly toxic therapies. There has also been cancer progression over this period. Further suppressing their immune system.

The other factor is as you pointed out , many patients started at suboptimal doses . The first patients started at a mouse dose.

Thats why LC is over the moon with excitement about “outstanding data”. Or “ we are collecting cancer data unlike anywhere else in the world “.

IMU will design further trials, with all of this knowledge in mind. This trial will give them the evidence needed to convince the FDA, that CF33 should be a first line of treatment. Because that’s what Ph1 trials do. They profuce the data requied to design the ph2 trials , that will enable progression to market.

Whilst many here may be unimpressed, LC is clearly very impressed. It’s worth remembering who the cancer trial expert is in this discussion.

The centrepiece of this trial is the fact that CF33 turns Cold Tumors to Hot Tumors.

That’s why LC is again pointing to the number of companies racing to get a foot hold in the CarT cellular therapy space. Because they will all want CF33 as an adjunct to their CarT therapies..

The first presentation of ONCARLYTICS will be on June 2 at ASCO . This is the last piece of the puzzle., If that data is good we are on our way to becoming the new SOC for cancer., IMU will take first prize in the race to beat cancer.,

Both Solid and Liquid tumors , 100% of the cancer market is ours. Between Azer-cel and CF33 we’ve got it covered.

Expand

Could you please post the announcement stating Imugene will be presenting at the ASCO Annual meeting? I must have missed it. Cheers

IMU Price at posting: 7.1¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 131 more messages in this thread...

First 48 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.0¢		Change 0.000(0.00%)		Mkt cap ! $371.8M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.8¢	$521.9K	10.58M

Buyers (Bids)

No.	Vol.	Price($)
17	1612511	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	3882781	14

View Market Depth

No.	Vol.	Price($)
17	1612511	0.049
48	6689431	0.048
42	4422304	0.047
49	3564481	0.046
60	9395068	0.045

Price($)	Vol.	No.
0.050	3882781	14
0.051	6352136	13
0.052	1742566	10
0.053	1865267	11
0.054	1735517	8

Last trade - 16.10pm 02/10/2024 (20 minute delay)

IMU (ASX) Chart

From the Professor..., page-48

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

From the Professor..., page-48

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News